The University of Sydney has announced an investment of $329.23m (A$478m) to build a 36,000m2 integrated health, education, and research precinct in New South Wales state, Australia.
According to the university, the Sydney Biomedical Accelerator (SBA) is its “largest ever capital investment” aimed at expediting research and healthcare in the state.
The Accelerator will be co-located at Royal Prince Alfred Hospital and the university’s Camperdown campuses, in the Tech Central precinct.
Architectural firms Denton Corker Marshall and HDR will design the SBA’s health education and research facilities.
Following a design contest, the university shortlisted the firms’ design that focused on ‘connectivity’.
While works for the accelerator will begin this year, initial occupation is slated to start from 2026.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
As part of the project, the architects will work in coordination with the university, Sydney Local Health District and other stakeholders for over 18 months to decide on final designs.
Additionally, to mark the collaboration between the university and the Royal Prince Alfred Hospital, the project will include a bridge connecting the two facilities.
The Accelerator will work towards addressing various health issues including cancer and neurodegenerative diseases and is expected to place Sydney as a key destination in biomedical research.
University of Sydney vice-chancellor and president professor Mark Scott AO said the project is being taken up by the university in collaboration with the Sydney Local Health District, NSW Government and Centenary Institute.
Scott added: “The range of world-class buildings and facilities that will make up the Sydney Biomedical Accelerator will bring together the brightest scientific and clinical minds with entrepreneurs, industry and government.”
The SBA will house nearly 1,200 biomedical researchers and clinician scientists, including over 800 laboratory researchers and PhD students and 100 industry researchers.
Furthermore, capabilities at the SBA and the university’s facilities at Westmead will be mapped together to enable shared access.